“Toxicity is the killer of ADCs” and remains the primary challenge limiting ADC success in the clinic. From unpredictable off-target effects to non-translating toxicity profiles and dose limiting toxicities, the industry must address key hurdles in preclinical models, patient selection, ADC design, and cross-disciplinary communication to accelerate the next wave of safer, more effective ADCs.

The 3rd ADC Toxicity Summit is the only industry-led event bringing together toxicology, pharmacology, translational science, and clinical development experts to accelerate bench-to-bedside-to-bench innovation by preventing, predicting, and mitigating toxicities to enhance ADC safety and clinical translation.